Use this page to scan recent stories from Medcitynews, see the themes that keep appearing, and jump into complete story briefs.
GSK’s Hibsago brings a new mechanism of action to chronic hepatitis B, targeting the genetic instructions the virus uses to make copies of itself and viral proteins. This drug was licensed from antisense oligonucleotide specialist Ionis Pharmaceuticals. The post GSK Wins FDA Nod for Novel Hepatitis B Drug Offering a Po
The GSK cancer immunotherapy Jemperli is now approved for treating advanced cases of rectal cancer harboring a particular genetic signature. It’s a label expansion for Jemperli, which was initially approved as a treatment for endometrial cancer. The post GSK Immunotherapy Gets Accelerated FDA Approval for Treating Rect
Cell and gene therapies are amazing medical breakthroughs but if we don’t find ways to pay for them, the development pipeline will fail. The post A Radical Proposal to Preserve Cell and Gene Therapy Innovation appeared first on MedCity News .
The Silence Therapeutics acquisition gives Merck KGaA a drug ready for a pivotal test in the blood disorder polycythemia vera. Silence’s RNA therapy offers a different approach and a potential dosing advantage over a Takeda Pharmaceutical product recently approved in this indication. The post Merck KGaA’s $1.1B Silence
This is not a discovery problem. It is a market entry and access problem, and it is far more tractable than the pipeline crisis we spend most of our attention on. The post The Antibiotics Exist —The System Cannot Deliver Them appeared first on MedCity News .
Epic will launch a tool in summer 2027 to help patients compare prescription cash prices and insurance costs across pharmacies. The post Why Epic Is Launching a Prescription Price Comparison Tool appeared first on MedCity News .
City Therapeutics’ lead RNA interference therapy could become an alternative to blockbuster-selling anticoagulants. The company’s technology for designing RNAi drugs and delivering them to tissues throughout the body has already led to partnerships with Bausch + Lomb in eye diseases and Biogen in central nervous system
In addition to a packed conference agenda and tours of the Pegasus Park healthcare and life science innovation hub in Dallas, INVEST Digital Health also includes an innovation showcase with novel health tech and medtech offerings as well as networking opportunities. The post INVEST Digital Health Celebrates Healthcare
Judi Health launched Judi Rx Retire, an employer-sponsored Medicare Part D plan designed to improve pricing transparency and streamline benefits administration. The post Judi Health Launches Medicare Part D Plan for Employers appeared first on MedCity News .
The Series A round was led by Define Ventures, with participation from Y Combinator and the California Health Care Foundation Innovation Fund. The post Readily Secures $11M for Compliance Intelligence Platform appeared first on MedCity News .
AdvaMed CEO Scott Whitaker outlined four policy priorities at the MedTech Conference: tariffs, FDA user fees, payment and coverage, and cybersecurity. The post AdvaMed’s 4 Policy Priorities, According to Its CEO appeared first on MedCity News .
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But Vertex Pharmaceuticals could also compete with a drug candidate from a recent acquisition. The post Startup OMass Secures $310M to Advance Drug for
Open the app view when you want faster scanning, saved stories, and source-focused reading in one place.